ADMA BIOLOGICS, INC. 8-K

What Happened

• On May 6, 2026, ADMA Biologics, Inc. announced and furnished a press release reporting its financial results for the three months ended March 31, 2026 and provided a business update. The press release is included in the 8-K as Exhibit 99.1.

Key Details

• Filing date: May 6, 2026 (Form 8-K, Item 2.02).
• Reporting period: three months ended March 31, 2026 (quarterly results/earnings).
• Press release attached as Exhibit 99.1 to the 8-K (Item 9.01(d) references the exhibit).
• The 8-K furnishes the press release (informational disclosure rather than a change in management or a material agreement).

Why It Matters

• This filing provides investors with ADMA’s latest quarterly earnings and a business update; those details can affect near-term stock performance and investor assessment of revenue, profitability, and operational progress. Investors should review the attached press release (Exhibit 99.1) for the specific financial figures and commentary, and monitor subsequent SEC filings or company communications for any additional context or investor calls.